Evidence map›Paper›PMID 33864843›Full record

ArticleAntiviral research2021

Antiviral activities of four marine sulfated glycans against adenovirus and human cytomegalovirus.

Mary Zoepfl, Rohini Dwivedi, Maggie C Taylor, Vitor H Pomin, Michael A McVoy

Open access · greenAbstract read
In one paragraph

Article in Antiviral research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Safety and Pharmacokinetics of Intranasally Administered Heparin.medRxiv : the preprint server for health sciences · 2022
    Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mary ZoepflDepartment of Chemistry, Virginia Commonwealth University, 1001 W Main St, Richmond, VA, 23284, USA.
Rohini DwivediDepartment of BioMolecular Sciences, University of Mississippi, 417A Faser Hall University, MS, 38677-1848, USA.
Maggie C TaylorDepartment of BioMolecular Sciences, University of Mississippi, 417A Faser Hall University, MS, 38677-1848, USA.
Vitor H PominDepartment of BioMolecular Sciences, University of Mississippi, 417A Faser Hall University, MS, 38677-1848, USA. Electronic address: vpomin@olemiss.edu.
Michael A McVoyDepartment of Pediatrics, Virginia Commonwealth University, 1101 E. Marshall Street, Richmond, VA, 23298-0163, USA. Electronic address: michael.mcvoy@vcuhealth.org.
University of Mississippi · USVirginia Commonwealth University · US

Funding

Tracking Glycosylation State with Fluorinated Glycosides ProbesP20GM130460 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI Joshua S Sharp · 2020 to 2026
$17.9M
Disruption of CS/KSPG-Mediated Neuronal Outgrowth InhibitionR03NS110996 · NINDS · UNIVERSITY OF MISSISSIPPI · PI POMIN, VITOR HUGO · 2020 to 2020
$142k
NIGMS NIH HHS P20 GM130460NINDS NIH HHS R03 NS110996
6 · The paper itself

Abstract

Broad-spectrum antivirals are more needed than ever to provide treatment options for novel emerging viruses and for viruses that lack therapeutic options or have developed resistance. A large number of viruses rely on charge-dependent non-specific interactions with heparan sulfate (HS), a highly sulfated glycosaminoglycan (GAG), for attachment to cell surfaces to initiate cell entry. As such, inhibitors targeting virion-HS interactions have potential to have broad-spectrum antiviral activity. Previous research has explored organic and inorganic small molecules, peptides, and GAG mimetics to disrupt virion-HS interactions. Here we report antiviral activities against both enveloped (the herpesvirus human cytomegalovirus) and non-enveloped (adenovirus) DNA viruses for four defined marine sulfated glycans: a sulfated galactan from the red alga Botryocladia occidentalis; a sulfated fucan from the sea urchin Lytechinus variegatus, and a sulfated fucan and a fucosylated chondroitin sulfate from the sea cucumber Isostichopus badionotus. As evidenced by gene expression, time of addition, and treatment/removal assays, all four novel glycans inhibited viral attachment and entry, most likely through interactions with virions. The sulfated fucans, which both lack anticoagulant activity, had similar antiviral profiles, suggesting that their activities are not only due to sulfation content or negative charge density but also due to other physicochemical factors such as the potential conformational shapes of these carbohydrates in solution and upon interaction with virion proteins. The structural and chemical properties of these marine sulfated glycans provide unique opportunities to explore relationships between glycan structure and their antiviral activities.

Indexed as

AdenoviridaeAntiviral AgentsAquatic OrganismsCell LineCytomegalovirusHeparan SulfateHumansPolysaccharidesRhodophytaSulfatesVirionVirus AttachmentAntiviral AgentsHeparan SulfatePolysaccharidesSulfatesAdenovirusAntiviralBroad-spectrumCytomegalovirusMarine sulfated glycansVirion attachment

Identifiers

PMID33864843
PMCPMC8212419
OpenAlexW3153557269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.